NZ329879A - Treating helicobacter infection with antigenic vaccine of lipopolysaccharide (lps) of helicobacter bacteria or fragment thereof - Google Patents

Treating helicobacter infection with antigenic vaccine of lipopolysaccharide (lps) of helicobacter bacteria or fragment thereof

Info

Publication number
NZ329879A
NZ329879A NZ329879A NZ32987995A NZ329879A NZ 329879 A NZ329879 A NZ 329879A NZ 329879 A NZ329879 A NZ 329879A NZ 32987995 A NZ32987995 A NZ 32987995A NZ 329879 A NZ329879 A NZ 329879A
Authority
NZ
New Zealand
Prior art keywords
helicobacter
lps
use according
infection
felis
Prior art date
Application number
NZ329879A
Other languages
English (en)
Inventor
Christopher Vincent Doidge
Adrian Lee
Fiona Jane Buck
Elizabeth Pietrzykowski
Charles Alexander Quinn
Ian George Barr
Michael John Kleinig
Original Assignee
Csl Limited And The University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Limited And The University filed Critical Csl Limited And The University
Publication of NZ329879A publication Critical patent/NZ329879A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/121—Helicobacter (G); Campylobacter (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
NZ329879A 1994-02-21 1995-02-17 Treating helicobacter infection with antigenic vaccine of lipopolysaccharide (lps) of helicobacter bacteria or fragment thereof NZ329879A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPM3995A AUPM399594A0 (en) 1994-02-21 1994-02-21 Antigenic preparation for treatment or prevention of helicobacter infection
NZ281146A NZ281146A (en) 1994-02-21 1995-02-17 Antigenic preparation of helicobacter bacteria lipopolysaccharide and its use in treating helicobacter infection

Publications (1)

Publication Number Publication Date
NZ329879A true NZ329879A (en) 1999-10-28

Family

ID=3778612

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ329879A NZ329879A (en) 1994-02-21 1995-02-17 Treating helicobacter infection with antigenic vaccine of lipopolysaccharide (lps) of helicobacter bacteria or fragment thereof
NZ281146A NZ281146A (en) 1994-02-21 1995-02-17 Antigenic preparation of helicobacter bacteria lipopolysaccharide and its use in treating helicobacter infection

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ281146A NZ281146A (en) 1994-02-21 1995-02-17 Antigenic preparation of helicobacter bacteria lipopolysaccharide and its use in treating helicobacter infection

Country Status (10)

Country Link
US (1) US6663873B2 (https=)
EP (1) EP0804489B1 (https=)
JP (1) JPH10500102A (https=)
KR (1) KR100351534B1 (https=)
AT (1) ATE222930T1 (https=)
AU (2) AUPM399594A0 (https=)
CA (1) CA2182274C (https=)
DE (1) DE69527986T2 (https=)
NZ (2) NZ329879A (https=)
WO (1) WO1995022563A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM399594A0 (en) * 1994-02-21 1994-03-17 Csl Limited Antigenic preparation for treatment or prevention of helicobacter infection
ATE310803T1 (de) * 1994-10-05 2005-12-15 Antex Biolog Inc Verfahren zur produktion von verstärkt antigen wirkenden heliobacter sp. und vakzine die diesen enthalten
US5897475A (en) * 1994-10-05 1999-04-27 Antex Biologics, Inc. Vaccines comprising enhanced antigenic helicobacter spp.
AU693679B2 (en) * 1995-04-21 1998-07-02 Csl Limited Protective helicobacter antigens
NZ304756A (en) * 1995-04-21 2000-02-28 Univ New South Wales Protective Helicobacter antigens and vaccine compositions containing them
AU6583398A (en) * 1997-03-26 1998-10-20 Avant Immunotherapeutics, Inc. Polypeptides which immunoreact with polyclonal antisera against (h. pylori)
GB9715702D0 (en) * 1997-07-24 1997-10-01 Univ Bristol Bacterial isolate
US6599509B2 (en) 1997-09-02 2003-07-29 Massachusetts Institute Of Technology Compositions and methods comprising helicobacter antigens for treatment and prevention of inflammatory bowel disease
JP4054681B2 (ja) * 2001-02-21 2008-02-27 デンカ生研株式会社 ヘリコバクター・ピロリを認識する抗体、およびヘリコバクター・ピロリを検出する方法
DE102004024674A1 (de) * 2004-05-18 2005-12-15 Wolfgang Lorenz Mittel und Verfahren zur Diagnose, Prophylaxe und Therapie von Bindegewebserkrankungen
EP1930025B1 (en) 2005-08-05 2013-05-01 The University of Tokushima ANTIGEN-AND-DRUG VEHICLE WHICH ENABLES THE CHANGEOVER FROM THE SELECTIVE PRODUCTION OF IgA ANTIBODY TO THE PRODUCTION OF BOTH OF IgA AND IgG ANTIBODIES, AND TRANSNASAL/TRANSMUCOSAL VACCINE USING THE VEHICLE
PL2945651T3 (pl) 2013-01-17 2018-08-31 Arsanis Biosciences Gmbh Przeciwciało swoiste wobec E.coli MDR
WO2015117711A1 (en) 2014-02-06 2015-08-13 Arsanis Biosciences Gmbh E. coli specific antibody sequences
WO2015124769A1 (en) 2014-02-24 2015-08-27 Glycovaxyn Ag Novel polysaccharide and uses thereof
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
CA3134216A1 (en) 2019-03-18 2020-09-24 Janssen Pharmaceuticals, Inc. Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
IL286467B2 (en) 2019-03-18 2026-02-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of polysaccharides E. coli o-antigen, preparations thereof and methods for using them
CN111467368B (zh) * 2020-04-13 2021-05-28 江南大学 含庚糖链的寡糖化合物在制备幽门螺旋杆菌疫苗中的应用
AU2021342797B2 (en) 2020-09-17 2024-02-08 Janssen Pharmaceuticals, Inc. Multivalent vaccine compositions and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU644121B2 (en) * 1989-12-04 1993-12-02 Auspharm International Limited Rapid in vitro test for helicobacter pylori using saliva
US5217872A (en) * 1990-02-27 1993-06-08 The United States Of America As Represented By The Department Of Health And Human Services Method for detection of borrelia burgdorferi antigens
US5098755A (en) * 1990-11-21 1992-03-24 Tanquary Albert C Textured thermoplastic elastomeric film, articles comprising same, and method of making such textured thermoplastic elastomeric film and articles
MX9301706A (es) 1992-04-13 1994-05-31 Oravax Inc Composicion de vacuna para el tratamiento de la infeccion por helicobacter.
WO1993022343A1 (en) * 1992-05-01 1993-11-11 The Rockfeller University Multiple antigen peptide system having adjuvant properties and vaccines prepared therefrom
US6258359B1 (en) * 1993-05-19 2001-07-10 Institut Pasteur Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions, and nucleic acid sequences encoding said polypeptides
US5871749A (en) * 1993-07-27 1999-02-16 Csl Limited Therapeutic treatment of H. pylori associated gastroduodenal disease
US6406703B1 (en) * 1993-07-27 2002-06-18 Csl Limited Treatment of H. pylori associated gastroduodenal disease
US5840302A (en) * 1993-11-10 1998-11-24 Bristol-Myers Squibb Company Treatment of bacterially-induced inflammatory diseases
AUPM399594A0 (en) * 1994-02-21 1994-03-17 Csl Limited Antigenic preparation for treatment or prevention of helicobacter infection
AUPM612494A0 (en) * 1994-06-08 1994-06-30 Csl Limited Treatment or prevention of helicobacter infection
US5897475A (en) * 1994-10-05 1999-04-27 Antex Biologics, Inc. Vaccines comprising enhanced antigenic helicobacter spp.
NZ304756A (en) * 1995-04-21 2000-02-28 Univ New South Wales Protective Helicobacter antigens and vaccine compositions containing them
US5997881A (en) * 1995-11-22 1999-12-07 University Of Maryland, Baltimore Method of making non-pyrogenic lipopolysaccharide or A
AU3458299A (en) * 1998-03-31 1999-10-18 United States Of America, As Represented By The Secretary Of Agriculture, The Monoclonal antibodies against (campylobacter jejuni) and (campylobacter coli) outer membrane antigens
US6576244B1 (en) * 1998-06-19 2003-06-10 Acambis, Inc. LT and CT in parenteral immunization methods against helicobacter infection

Also Published As

Publication number Publication date
CA2182274C (en) 2007-05-22
AU1801195A (en) 1995-09-04
NZ281146A (en) 1998-04-27
EP0804489B1 (en) 2002-08-28
KR100351534B1 (ko) 2003-03-15
AUPM399594A0 (en) 1994-03-17
EP0804489A1 (en) 1997-11-05
ATE222930T1 (de) 2002-09-15
WO1995022563A1 (en) 1995-08-24
US6663873B2 (en) 2003-12-16
JPH10500102A (ja) 1998-01-06
KR970701209A (ko) 1997-03-17
HK1004677A1 (en) 1998-12-04
DE69527986D1 (de) 2002-10-02
DE69527986T2 (de) 2003-04-10
AU693864B2 (en) 1998-07-09
EP0804489A4 (https=) 1997-11-19
US20020122794A1 (en) 2002-09-05
CA2182274A1 (en) 1995-08-24

Similar Documents

Publication Publication Date Title
AU693864B2 (en) Antigenic preparation for treatment or prevention of helicobacter infection
US5538729A (en) Oral treatment of helicobacter infection
Czinn et al. Protection of germ-free mice from infection by Helicobacter felis after active oral or passive IgA immunization
JP6121907B2 (ja) 広域の、非定型の、または混合の臨床応用における治療のための組成物および方法
Van den Broeck et al. Induction of immune responses in pigs following oral administration of purified F4 fimbriae
EP0771214B1 (en) Treatment and prevention of helicobacter infection
BRPI0316018B1 (pt) vacina polissacarídica para infecções estafilocócicas
Casswall et al. Bovine anti-Helicobacter pylori antibodies for oral immunotherapy
EP0909272B1 (en) Helicobacter pylori adhesin binding group antigen
US5961985A (en) Vaccine and serum for endotoxin associated disease immunization and treatment, detoxified endotoxin, and bacterial mutant
JP3169608B2 (ja) ヒトにおいてエンテロトキシン産生大腸菌により起こる腸感染症／下痢に対して接種するためのホルマリン殺菌したコロニー形成因子抗原（ｃｆａ）−発現性大腸菌の調製および使用
EP1784417B1 (en) Fusobacterium polypeptides and methods of use
EP0215131A1 (en) E87Ag ANTIGEN OF PSEUDOMONAS AERUGINOSA, MONOCLONAL ANTIBODY AGAINST IT, AND HYBRIDOMA
Butscher et al. The therapeutic action of monoclonal antibodies against a surface glycoprotein of Giardia muris
HK1004677B (en) Antigenic preparation for treatment or prevention of helicobacter infection
Feodorova et al. Adjuvant effect of anti-idiotypic antibodies to Yersinia pestis lipopolysaccharide
AU675938C (en) Oral treatment of helicobacter infection
HK40002785A (en) Compositions and methods for treatment in broad-spectrum, undifferentiated or mixed clinical applications
YOKOYAMA et al. Passage of Chicken Egg Yolk Antibody Treated with Hydroxypropyl Methylcellulose Phthalate in the Gastrointestinal Tract of Calves Yutaka IKEMORI, Masashi OHTA, Kouji UMEDA, Robert C. PERALTA, Masahiko KUROKI
HK1189835B (en) Compositions and methods for treatment in broad-spectrum, undifferentiated or mixed clinical applications
HK1189835A (en) Compositions and methods for treatment in broad-spectrum, undifferentiated or mixed clinical applications
JP2003012550A (ja) ヘリコバクター・ピロリ感染症の予防及び治療剤

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired